Defactinib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Defactinib. Educational only — not medical advice.
Labeled uses
AVMAPKI FAKZYNJA CO-PACK is indicated for the treatment of adult patients with KRAS -mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. This indication is approved under accelerated approval based on tumor response rate and duration of response [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Source: FDA labeling via NIH DailyMed (set 65889527…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.